A case study of lung adenocarcinoma (LUAD) highlights known biomarkers (KRAS, EGFR, STK11), key proteins (SOCS1, HSPA8, SMC3), and drugs (Erlotinib, Palbociclib) that are consistent with the literature.<h4>Conclusions</h4>In conclusion, BKDRP presents a novel biological knowledge-driven deep neural network model for cancer drug response prediction that shows strong predictive accuracy and interpretability. This evidence concerns the gene KRAS and lung adenocarcinoma.